SEC Form 4 · accession 0001682852-26-000139
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R. McDonnell
Director
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 5:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001682852
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $73.80 | Jul 8, 2026 | A | 7,415 | A | — | Jul 8, 2036 | Common Stock | 7,415 | 7,415 | D |
| Restricted Stock UnitsF2,F3 | — | Jul 8, 2026 | A | 1,618 | A | — | — | Common Stock | 1,618 | 1,618 | D |
| Restricted Stock UnitsF2,F4 | — | Jul 8, 2026 | A | 5,733 | A | — | — | Common Stock | 5,733 | 5,733 | D |
Explanation of responses
- F1This option will become fully vested and exercisable on July 8, 2027.
- F2Restricted stock units convert into common stock on a one-for-one basis.
- F3The shares subject to this restricted stock unit award will vest in full on July 8, 2027.
- F4The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.